berubicin

Berubicin is a synthetic small molecule and a 4'-O-benzylated analogue of the anthracycline derivative doxorubicin, developed specifically to cross the blood-brain barrier. It acts as a potent topoisomerase II inhibitor by intercalating into DNA, thereby disrupting DNA replication, repair, and RNA/protein synthesis. Unlike other anthracyclines, berubicin can circumvent multidrug resistance mechanisms such as P-glycoprotein and MRP1-mediated efflux. Its primary indication is for brain cancers—especially glioblastoma multiforme—where it has shown promising activity in clinical trials with durable responses in some patients. Berubicin was originally developed by Dr. Waldemar Priebe at The University of Texas MD Anderson Cancer Center and has been further advanced by CNS Pharmaceuticals[1][2][4][5][6][7].

Brand names

Cecenu

Other names

berubicin hydrochlorideBerubicin [INN]UNII-6QPN83HK2MUNII6QPN83HK2MUNII 6QPN83HK2M